Enhanced Stent Retriever Treats Ischemic Stroke
|
By HospiMedica International staff writers Posted on 30 May 2018 |

Image: The upgraded EmboTrap II stent retriever (Photo courtesy of Cerenovus).
A next-generation stent retriever captures and removes life-threatening blood clots from the brain following an ischemic stroke.
The Cerenovus (Irvine, CA, USA) EmboTrap II revascularization device is intended to restore blood flow in the neurovasculature by removing thrombii in patients experiencing ischemic stroke within eight hours of symptom onset. The 0.021”, microcatheter compatible clot retriever is designed to trap blood clots with minimum compression, rapidly deliver thrombolysis in cerebral infarction (TICI) 2b-3 reperfusion therapy, and retain the clots during removal to protect the patient from distal embolisms.
The EmboTrap II, which is available in both 5×33 and 5×21 sizes, features an inner channel that allows bypass while open, and five chambers to improve the clot-device interaction. The device also has a distal section with an extensive mesh designed to keep the clot in place, so that it does not fragment. The analysis of revascularisation in ischemic stroke with EmboTrap (ARISE II) study showed a final procedural reperfusion rate of 92.5% among acute ischemic stroke patients with large vessel occlusion within three passes of the EmboTrap II.
“Embotrap II is the product of deep collaboration between engineers and clinicians to better understand the science of blood clot, what causes them to form and how a mechanical thrombectomy device can interact with them to help improve outcomes,” said Daniella Cramp, worldwide president of Cerenovus. “Cerenovus is committed to advancing treatment with evidence-based solutions so that fewer and fewer people are affected by the ravages of stroke.”
“The EmboTrap platform has been a great addition to my clinical practice. In my first nine cases using the device, I was able to get TICI 2b-3 reperfusion in one pass. Now, with the EmboTrap II, I’ve had comparably good results when treating longer occlusions,” said professor of radiology Christian Taschner, MD, of the University of Freiburg (Germany). “The open design of the device helps trap clot inside and also makes it quite flexible, which is important when removing clot from the arteries of the brain.”
Stent retrievers are deployed in an occluded vessel and are temporarily expanded into the body of a thrombus in order to recanalize the vessel, allowing for reperfusion of ischemic sites and causing the thrombus to be partially entangled within the stent. Thrombectomy is then performed by retracting the stent.
Related Links:
Cerenovus
The Cerenovus (Irvine, CA, USA) EmboTrap II revascularization device is intended to restore blood flow in the neurovasculature by removing thrombii in patients experiencing ischemic stroke within eight hours of symptom onset. The 0.021”, microcatheter compatible clot retriever is designed to trap blood clots with minimum compression, rapidly deliver thrombolysis in cerebral infarction (TICI) 2b-3 reperfusion therapy, and retain the clots during removal to protect the patient from distal embolisms.
The EmboTrap II, which is available in both 5×33 and 5×21 sizes, features an inner channel that allows bypass while open, and five chambers to improve the clot-device interaction. The device also has a distal section with an extensive mesh designed to keep the clot in place, so that it does not fragment. The analysis of revascularisation in ischemic stroke with EmboTrap (ARISE II) study showed a final procedural reperfusion rate of 92.5% among acute ischemic stroke patients with large vessel occlusion within three passes of the EmboTrap II.
“Embotrap II is the product of deep collaboration between engineers and clinicians to better understand the science of blood clot, what causes them to form and how a mechanical thrombectomy device can interact with them to help improve outcomes,” said Daniella Cramp, worldwide president of Cerenovus. “Cerenovus is committed to advancing treatment with evidence-based solutions so that fewer and fewer people are affected by the ravages of stroke.”
“The EmboTrap platform has been a great addition to my clinical practice. In my first nine cases using the device, I was able to get TICI 2b-3 reperfusion in one pass. Now, with the EmboTrap II, I’ve had comparably good results when treating longer occlusions,” said professor of radiology Christian Taschner, MD, of the University of Freiburg (Germany). “The open design of the device helps trap clot inside and also makes it quite flexible, which is important when removing clot from the arteries of the brain.”
Stent retrievers are deployed in an occluded vessel and are temporarily expanded into the body of a thrombus in order to recanalize the vessel, allowing for reperfusion of ischemic sites and causing the thrombus to be partially entangled within the stent. Thrombectomy is then performed by retracting the stent.
Related Links:
Cerenovus
Latest Critical Care News
- Noninvasive Monitoring Device Enables Earlier Intervention in Heart Failure
- Automated IV Labeling Solution Improves Infusion Safety and Efficiency
- First-Of-Its-Kind AI Tool Detects Pulmonary Hypertension from Standard ECGs
- 4D Digital Twin Heart Model Improves CRT Outcomes
- AI Turns Glucose Data Into Actionable Insights for Diabetes Care
- Microscale Wireless Implant Tracks Brain Activity Over Time
- Smart Mask Delivers Continuous, Battery-Free Breath Monitoring
- Routine Blood Pressure Readings May Identify Risk of Future Cognitive Decline
- CGM-Based Algorithm Enhances Insulin Dose Adjustment in Type 2 Diabetes
- Fish Scale–Based Implants Offer New Approach to Corneal Repair
- Dual-Function Wound Patch Combines Infection Sensing and Treatment
- Smartwatch Signals and Blood Tests Team Up for Early Warning on Insulin Resistance
- Smart Fabric Technology Aims to Prevent Pressure Injuries in Hospital Care
- Standardized Treatment Algorithm Improves Blood Pressure Control
- Combined Infection Control Strategy Limits Drug-Resistant Outbreak in NICU
- AI Helps Predict Which Heart-Failure Patients Will Worsen Within a Year
Channels
Artificial Intelligence
view channelAI Analysis of Pericardial Fat Refines Long-Term Heart Disease Risk
Accurately identifying long-term cardiovascular disease risk in asymptomatic adults remains challenging for clinicians. Missed or underestimated risk delays preventive therapy and increases the chance... Read more
Machine Learning Approach Enhances Liver Cancer Risk Stratification
Hepatocellular carcinoma, the most common form of primary liver cancer, is often detected late despite targeted surveillance programs. Current screening guidelines emphasize patients with known cirrhosis,... Read moreSurgical Techniques
view channel
Ultrasound Technology Aims to Replace Invasive BPH Procedures
Benign prostatic hyperplasia (BPH) is a frequent cause of lower urinary tract symptoms in aging men and often requires invasive procedures or prolonged recovery. With prevalence expected to rise as populations... Read more
Continuous Monitoring with Wearables Enhances Postoperative Patient Safety
Postoperative hypoxemia on general surgical wards is common and often missed by intermittent vital sign checks. Undetected low oxygen levels can delay recovery and raise the risk of complications that... Read morePatient Care
view channel
Wearable Sleep Data Predict Adherence to Pulmonary Rehabilitation
Chronic obstructive pulmonary disease (COPD) is a long-term lung disorder that makes breathing difficult and often disturbs sleep, reducing energy for daily activities. Limited engagement in pulmonary... Read more
Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care
More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read moreHealth IT
view channel
EMR-Based Tool Predicts Graft Failure After Kidney Transplant
Kidney transplantation offers patients with end-stage kidney disease longer survival and better quality of life than dialysis, yet graft failure remains a major challenge. Although a successful transplant... Read more
Printable Molecule-Selective Nanoparticles Enable Mass Production of Wearable Biosensors
The future of medicine is likely to focus on the personalization of healthcare—understanding exactly what an individual requires and delivering the appropriate combination of nutrients, metabolites, and... Read moreBusiness
view channel







